Scholar Rock’s stock is due to drop by 7.49% following the news, according to pre-market estimates. CAMBRIDGE, Mass., March 16, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical ...
Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...
Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other ...
1 Day SRRK -1.75% DJIA 0.08% S&P Mid Cap 400 -0.51% Health Care/Life Sciences 0.25% ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback